KUALA LUMPUR, Jan 17 (Bernama) -- Single Use Support, an innovative process solution provider has established the groundwork for an exciting new year ahead, anticipating further growth across its global operations.
In a statement, the Austrian-based provider said following strong growth of COVID-related projects in previous years, it grew its non-COVID business by more than 70 per cent in 2023.
The continued growth of the business is secured by a significant increase in personnel, in which the provider grew its workforce to over 170 employees, an increase of more than 40 per cent over the last six months.
“Together with our team and with our customers we will continue to grow by offering innovative solutions that address the daily challenges faced by manufacturers in the biopharma industry,” said its Chief Executive Officer, Christian Praxmarer who is fully committed to continuing the company’s success story.
Meanwhile, its Chief Financial Officer, Christopher Dürolf said: “Based on our current order backlog and ongoing project tenders, we feel confident that we can deliver strong non-COVID-related year-over-year growth in 2024.”
Single Use Support’s award-winning solutions continued to gain significant traction among major pharmaceutical companies and contract development and manufacturing organisations (CDMOs) globally.
Several well-known industry participants have already placed significant orders for consumables and platform systems designed to aliquot, freeze/thaw, store, and ship high-value drug substances.
Single Use Support serves the most innovative and prominent pharmaceutical companies to develop novel therapies and advanced lifesaving therapeutics.
The fluid management specialist covers well-established drug classes such as monoclonal antibodies as well as emerging therapeutics in areas such as cell and gene therapies, antibody-drug conjugates, and others.
-- BERNAMA
No comments:
Post a Comment